Good outcomes relative to bariatric surgery after catheter ablation in observational data ...

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

GLP receptor agonists tied to lower substance use disorder risk in veterans, reducing emergency visits, hospitalizations, and overdose incidents.

Dublin, March 04, 2026 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for GLP-1 ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet. Retatrutide is a triple-agonist ...

SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient ...

Indianapolis-based Eli Lilly just logged another big win in the metabolic medicine race, reporting that its experimental triple-agonist drug retatrutide cleared a late-stage trial in people with type ...

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

Tue, December 16, 2025 at 8:44 PM UTC Eli Lilly, which makes Zepbound and Mounjaro, just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...